Sanofi

Sanofi opened higher and rallied intraday, gaining 3.3% to $43.02 as of 10:20 AM ET, driven by positive Phase 3 results for Nexviazyme in infantile-onset Pompe disease and improved outcomes for Dupilumab in a Phase 2 eosinophilic gastritis trial. Despite Q1 revenue rising 12.24% YoY to $12.9B and net profit surging 296.6% YoY to $1.85B, the stock is down 10.8% YTD and trades 18.34% below its 52-week high of $52.68, while also below the 60-day MA of $44.42, suggesting market concerns over an EU antitrust probe are already priced in. However, Q1 EPS of $0.768 fell 6.47% YoY, leaving earnings sustainability in question.